<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04712643</url>
  </required_header>
  <id_info>
    <org_study_id>ML42612</org_study_id>
    <nct_id>NCT04712643</nct_id>
  </id_info>
  <brief_title>A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma</brief_title>
  <official_title>A Phase III, Open-Label, Randomized Study of On-Demand TACE Combined With Atezolizumab Plus Bevacizumab (Atezo/Bev) or On-Demand TACE Alone in Patients With Untreated Heaptocellular Carcionma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of atezolizumab plus bevacizumab combined&#xD;
      with on-demand TACE compared to on-demand TACE alone in participants with hepatocellular&#xD;
      carcinoma who are unsuitable for curative therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2021</start_date>
  <completion_date type="Anticipated">February 26, 2027</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TACE Progression-Free Survival (TACE PFS) as Determined by IRC</measure>
    <time_frame>Randomization to untreatable progression or TACE failure/refractoriness or death (up to approximately 48 months)</time_frame>
    <description>TACE PFS is defined as the time from randomization to untreatable progression or TACE failure/refractoriness and any cause of death, as determined by the independent review committee (IRC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Randomization to death from any cause (up to approximately 72 months)</time_frame>
    <description>Overall survival (OS) after enrollment is defined as the time from randomization to death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TACE PFS as Determined by Investigator</measure>
    <time_frame>Randomization to untreatable progression or TACE failure/refractoriness or death (up to approximately 48 months)</time_frame>
    <description>TACE PFS as determined by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Untreatable (unTACEable) Progression (TTUP)</measure>
    <time_frame>Randomization to Child-Pugh B8 or worse, intrahepatic tumor progression, with new lesions NOT defined as tumor progression, MVI or EHS (up to approximately 48 months)</time_frame>
    <description>Time to untreatable (unTACEable) progression (TTUP) is defined as time from randomization to Child-Pugh B8 or worse, intrahepatic tumor progression, with new lesions NOT defined as tumor progression, MVI or EHS, as determined by the IRC and investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Randomization to unTACEable progression or TACE failure/refractoriness (up to approximately 48 months)</time_frame>
    <description>Time to progression (TTP) is defined as the time from randomization to unTACEable progression or TACE failure/refractoriness, as determined by the IRC and investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Macrovascular Invasion (MVI)</measure>
    <time_frame>Ranodimzation to first evidence of MVI (up to approximately 48 months )</time_frame>
    <description>Time to MVI is defined as the time from randomization to the first evidence of MVI, as determined by the IRC and investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Extrahepatic Spread (EHS)</measure>
    <time_frame>Randomization to first evidence of EHS (up to approximately 48 months)</time_frame>
    <description>Time to EHS is defined as the time from randomization to the first evidence of EHS, as determined by the IRC and investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to MVI/EHS</measure>
    <time_frame>Randomization to first evidence of MVI/EHS (up to approximately 48 months)</time_frame>
    <description>Time to MVI/EHS is defined as the time from randomization to the first evidence of MVI/EHS (whichever occurs first), as determined by the IRC and investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Randomization up to approximately 72 months</time_frame>
    <description>Objective response rate (ORR) is defined as the percentage of participants who have a complete or partial response, as determined by the IRC and investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Responses (DOR)</measure>
    <time_frame>First occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first)(up to approximately 72 months)</time_frame>
    <description>Duration of responses (DOR) is defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first), as determined by the IRC and investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration (TTD)</measure>
    <time_frame>Randomization to first deterioration (up to approximately 72 months)</time_frame>
    <description>TTD is defined as the time from randomization to first deterioration in the patient-reported GHS/QoL, physical function, or role function scales of the EORTC QLQ-C30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Baseline up to apporximately 72 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">342</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A: atezolizumab + bevacizumab + TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive atezolizumab plus bevacizumab on Day 1 of a 21-Day cycle, after every on-demand transarterial chemoembolization procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: TACE alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive on-demand transarterial chemoembolization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until participant experience loss of clinical benefit as evaluated by the investigator or unacceptable toxicity or withdrawal of informed consent.</description>
    <arm_group_label>Arm A: atezolizumab + bevacizumab + TACE</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Becavizumab</intervention_name>
    <description>Bevacizumab will be administered by IV infusion at a fixed dose of 15 mg/kg on Day 1 of each 21-day Cycle.</description>
    <arm_group_label>Arm A: atezolizumab + bevacizumab + TACE</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transarterial chemoembolization (TACE)</intervention_name>
    <description>TACE will be performed by clinical demand.</description>
    <arm_group_label>Arm A: atezolizumab + bevacizumab + TACE</arm_group_label>
    <arm_group_label>Arm B: TACE alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of HCC by histology/ cytology or clinical criteria&#xD;
&#xD;
          -  Eligible for TACE treatment&#xD;
&#xD;
          -  No prior systemic therapy for HCC, especially immunotherapy&#xD;
&#xD;
          -  No prior locoregional therapy to the target lesion(s)&#xD;
&#xD;
          -  At least one measurable untreated lesion&#xD;
&#xD;
          -  ECOG Performance Status of 0-1&#xD;
&#xD;
          -  Child-Pugh class A&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of macrovascular invasion (MVI)&#xD;
&#xD;
          -  Evidence of extrahepatic spread (EHS)&#xD;
&#xD;
          -  Being a candidate for curative treatments&#xD;
&#xD;
          -  Any condition representing a contraindication to TACE as determined by the&#xD;
             investigators&#xD;
&#xD;
          -  Active or history of autoimmune disease or immune deficiency&#xD;
&#xD;
          -  Untreated or incompletely treated esophageal and/or gastric varices with bleeding or&#xD;
             high risk for bleeding&#xD;
&#xD;
          -  A prior bleeding event due to esophageal and/or gastric varices within 6 months prior&#xD;
             to initiation of study treatment&#xD;
&#xD;
          -  Evidence of bleeding diathesis or significant coagulopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: ML42612 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing City</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing You An Hospital; Digestive Dept</name>
      <address>
        <city>Beijing City</city>
        <zip>100069</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Tsinghua Changgung Hospital</name>
      <address>
        <city>Beijing City</city>
        <zip>102218</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha City</city>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sichuan Cancer Hospital</name>
      <address>
        <city>Chengdu City</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University; Surgical Oncology</name>
      <address>
        <city>Chengdu City</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Of Fujian Medical University</name>
      <address>
        <city>Fuzhou City</city>
        <zip>350005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sun Yet-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital; internal medicine</name>
      <address>
        <city>Harbin City</city>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)</name>
      <address>
        <city>Nanjing City</city>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing City</city>
        <zip>211100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan Unvierstiy</name>
      <address>
        <city>Shanghai City</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>ShenYang</city>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital; Surgical Department</name>
      <address>
        <city>Tianjin City</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital</name>
      <address>
        <city>Wuhan</city>
        <zip>430079</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiaotong University; Hepatobiliary surgery Department</name>
      <address>
        <city>Xi'an</city>
        <zip>710049</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Zhejiang</city>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhuhai People's Hospital</name>
      <address>
        <city>Zhuhai</city>
        <zip>519099</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center</name>
      <address>
        <city>Aichi</city>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiba University Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Medical Center</name>
      <address>
        <city>Kanagawa</city>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center</name>
      <address>
        <city>Kanagawa</city>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kitasato University Hospital</name>
      <address>
        <city>Kanagawa</city>
        <zip>252-0375</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>November 13, 2021</last_update_submitted>
  <last_update_submitted_qc>November 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here ( https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

